Chicken eggs containing human proteins could be key for future therapies

| January 28, 2019

article image
Genetically modified chickens could produce human proteins in their eggs, offering a cost-effective method of producing certain drugs. Researchers at University of Edinburgh’s Roslin Institute and Roslin Technologies initially focused on the production of high-quality proteins so they could be used in research, but found that the drugs produced worked as well as the proteins produced during existing methods. Using a simple purification method, high quantities of the protein could be recovered from the eggs, with no adverse effect on the chickens themselves.

Spotlight

ProPharma Group

ProPharma Group is an industry leader providing pharmacovigilance, medical information, validation, compliance and technical services to the pharmaceutical, biotechnology, medical device and related industries. We enable our clients to deliver their products to patients in the most safe, compliant, and timely manner possible. Backed by years of experience, our highly trained team understands the needs companies have in this heavily regulated environment. ProPharma Group's experts custom tailor solutions for each of our clients based upon their needs and goals.

OTHER ARTICLES

Pfizer Won’t Win the Coronavirus Pharma War

Article | March 6, 2020

Shares of Pfizer jumped more than 6% on Wednesday, after the company announced a plan to test some of its antiviral products as a potential treatment for the coronavirus from China. More than 35 million shares traded on the news — about 48% more than normal — as investors looked for any positive news from the pharma community after the recent selloff. So, does this mean that Pfizer stock is turning the corner?

Read More

Top Specialty Pharmacy Therapy Areas

Article | March 16, 2020

Accelerated by advancements in cancer treatments and a growing emphasis on personalized and precision medicine, specialty pharmacy represents a rapidly growing sector within the healthcare industry. In fact, the market is projected to grow to $500 billion by the end of this year—up from $200 billion in total U.S. specialty drug spending in 2017. Industry growth of this magnitude creates challenges for those looking to understand and penetrate the market. It can be difficult, after all, to maintain updated information about high-priority drug therapy areas or facility affiliations in a market that’s constantly changing.

Read More

Five Ways to Manage Your Trial Effectively in a Fast-Changing Global Environment

Article | March 11, 2020

Over the past half-century, clinical trials have grown increasingly complex. A flood of new data from novel sources combined with more elaborate study designs and tougher regulatory standards have lengthened timelines and hiked costs, contributing to a steady decline of efficiency. It all adds up: Nearly half of all drug launches underperform revenue expectations. And if that isn’t enough, the outbreak of COVID-19 worldwide is having an effect on how life sciences companies operate their businesses, including how clinical trials are conducted. Most clinical trial research organizations have tried to adapt by tweaking a platform here, adding a new app there, but this has only yielded patchwork systems of sites, spreadsheets and dashboards that further burden the process.

Read More

Do Clinical Trial Delays Mean Trouble for Pharmaceutical Stocks?

Article | April 1, 2020

Pharmaceutical stocks have been somewhat of a safe haven for investors as the coronavirus outbreak spread from China to the rest of the world. But as the pandemic deepened, now resulting in more than 782,000 cases worldwide, even these "safer" companies are beginning to feel the effects. The U.S. is now the coronavirus epicenter, with the most cases -- more than 161,000 as of today. Initial concerns for drugmakers had to do with the supply of active pharmaceutical ingredients, which often come from China. The worry was that pharmaceutical companies wouldn't be able to produce enough of their drugs for patients.

Read More

Spotlight

ProPharma Group

ProPharma Group is an industry leader providing pharmacovigilance, medical information, validation, compliance and technical services to the pharmaceutical, biotechnology, medical device and related industries. We enable our clients to deliver their products to patients in the most safe, compliant, and timely manner possible. Backed by years of experience, our highly trained team understands the needs companies have in this heavily regulated environment. ProPharma Group's experts custom tailor solutions for each of our clients based upon their needs and goals.

Events